Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to buy now. In a report released on July ...

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...